Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) Operating Income (2023 - 2025)

Historic Operating Income for Mereo BioPharma (MREO) over the last 3 years, with Q3 2025 value amounting to -$10.0 million.

  • Mereo BioPharma's Operating Income fell 684.95% to -$10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.0 million, marking a year-over-year decrease of 1982.91%. This contributed to the annual value of -$47.4 million for FY2024, which is 6668.07% down from last year.
  • According to the latest figures from Q3 2025, Mereo BioPharma's Operating Income is -$10.0 million, which was down 684.95% from -$10.5 million recorded in Q2 2025.
  • Mereo BioPharma's 5-year Operating Income high stood at -$811000.0 for Q2 2023, and its period low was -$15.3 million during Q4 2024.
  • For the 3-year period, Mereo BioPharma's Operating Income averaged around -$9.8 million, with its median value being -$10.0 million (2025).
  • In the last 5 years, Mereo BioPharma's Operating Income plummeted by 148002.47% in 2024 and then surged by 1806.62% in 2025.
  • Over the past 3 years, Mereo BioPharma's Operating Income (Quarter) stood at -$7.1 million in 2023, then crashed by 114.3% to -$15.3 million in 2024, then skyrocketed by 34.44% to -$10.0 million in 2025.
  • Its Operating Income was -$10.0 million in Q3 2025, compared to -$10.5 million in Q2 2025 and -$11.2 million in Q1 2025.